RPRX — Recent News Coverage
All news mentioning RPRX in ESEN's AI-graded feed
News stories with RPRX as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on RPRX. See /coverage/RPRX for the 30-day aggregate.
INSIDERMONKEY.COM
·
2026-08-13
LOW
NEUTRAL
CORR0.52
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
$RPRX
$AZN
◈ ESEN AI
This article presents a comparative analysis of two distinct biopharma business models: Royalty Pharma (RPRX), which acquires royalty streams from approved drugs, versus AstraZeneca (AZN), which pursues integrated drug …
SEEKINGALPHA.COM
·
2026-08-05
HIGH
BULLISH
CORR0.72
Royalty Pharma targets $3.4B-$3.5B 2026 portfolio receipts as it raises guidance again (NASDAQ:RPRX)
$RPRX
◈ ESEN AI
Royalty Pharma (RPRX) delivered a material earnings beat with upward guidance revision for 2026, targeting $3.4B–$3.5B in portfolio receipts. This marks the second consecutive guidance raise, signaling management confid…
SEEKINGALPHA.COM
·
2026-08-05
NEUTRAL
NEUTRAL
CORR0.42
Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript
$RPRX
◈ ESEN AI
Royalty Pharma (RPRX) released Q2 2026 earnings results via conference call, marking standard quarterly disclosure without headline-grabbing developments or guidance revisions evident from the transcript summary. Earnin…
RTTNEWS.COM
·
2026-08-05
NEUTRAL
NEUTRAL
CORR0.42
Royalty Pharma Q2 Net Income Declines; Raises 2026 Guidance For Portfolio Receipts
$RPRX
◈ ESEN AI
Royalty Pharma (RPRX) reported mixed Q2 results, with net income declining 44% year-over-year to $18 million while adjusted EBITDA expanded to $736 million from $633 million. This divergence suggests operational profita…
MANILATIMES.NET
·
2026-08-05
NEUTRAL
BULLISH
CORR0.58
Royalty Pharma reports second quarter 2026 results
$RPRX
◈ ESEN AI
Royalty Pharma (RPRX) delivered Q2 2026 results with solid operational momentum, posting 6% Portfolio Receipts growth to $773 million and notably stronger 14% Royalty Receipts expansion. The company generated $728 milli…
SEEKINGALPHA.COM
·
2026-08-05
LOW
NEUTRAL
CORR0.42
Royalty Pharma: At The Right P/E, I'm In (But Not Here) (NASDAQ:RPRX)
$RPRX
◈ ESEN AI
RPRX operates within the niche but structurally resilient pharmaceutical royalty ecosystem, where revenue streams derive from milestone payments and long-term licensing agreements rather than direct drug development. Th…
MANILATIMES.NET
·
2026-07-17
LOW
NEUTRAL
CORR0.15
Royalty Pharma declares third quarter 2026 dividend
$RPRX
◈ ESEN AI
Royalty Pharma (RPRX) announced a Q3 2026 dividend of $0.235 per Class A ordinary share, a routine capital allocation decision by the board. This represents standard shareholder distribution activity rather than a funda…
MANILATIMES.NET
·
2026-07-15
LOW
NEUTRAL
CORR0.15
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
$RPRX
◈ ESEN AI
Royalty Pharma (RPRX) has scheduled its Q2 2026 earnings announcement for August 5, 2026, with a corresponding investor call at 8:00 a.m. ET. This is a standard earnings calendar notification that provides transparency …
ZACKS.COM
·
2026-07-10
NEUTRAL
BULLISH
CORR0.52
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
$RPRX
◈ ESEN AI
Royalty Pharma (RPRX) has reached a 52-week high, signaling sustained investor confidence in the biopharmaceutical royalty income model. The company's business structure—acquiring milestone payments and royalties from d…
EXPLORE OTHER FILTERS